Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To determine whether thiazolidinedione use is associated with a risk of bladder cancer. Methods: We searched MEDLINE and EMBASE in J une 2012 (with P ub M ed update to J uly 2013) and conducted meta‐analysis on the overall risks of bladder cancer with pioglitazone or rosiglitazone and the risk with different categories of cumulative dose or duration of drug use. Results: We screened 230 citations and included 18 studies, comprising five randomized controlled trials ( RCT s) and 13 observational studies. Meta‐analysis showed a significantly higher overall risk of bladder cancer with pioglitazone in RCT s [7878 participants; odds ratio ( OR ) 2.51, 95% confidence interval ( CI ) 1.09–5.80] and observational studies (>2.6 million patients; OR for ‘ever’ users vs . non‐users 1.21, 95% CI 1.09–1.35). Subgroup analysis of observational studies by cumulative dose showed the risk of bladder cancer to be greatest with >28.0 g of pioglitazone ( OR 1.64, 95% CI 1.28–2.12). A significantly increased risk was found with both 12–24 months ( OR 1.41, 95% CI 1.16–1.71) and >24 months ( OR 1.51, 95% CI 1.26–1.81) cumulative durations of pioglitazone exposure. No significant risk was seen with rosiglitazone in RCTs ( OR 0.84, 95% CI 0.35–2.04) or ‘ever’ users vs . non‐users in observational studies ( OR 1.03, 95% CI 0.94–1.12); the evidence for any relationship between bladder cancer risk and rosiglitazone cumulative duration is limited and inconsistent. Direct comparison of pioglitazone to rosiglitazone ‘ever’ users yielded an OR of 1.25 (95% CI 0.91–1.72). Conclusions: A modest but clinically significant increase in the risk of bladder cancer with pioglitazone was found, which appears to be related to cumulative dose and duration of exposure. We recommend that prescribers limit pioglitazone use to shorter durations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Analysing Data and Undertaking Meta‐Analyses
Deeks, J. J., Higgins, J. P., & Altman, D. G. (2008) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9780470712184.ch9 · Cited by 1,800
The appropriateness of asymmetry tests for publication bias in meta-analyses: A large survey
Ioannidis, J. P. A., & Trikalinos, T. A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.060410 · Cited by 1,052
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L. (2011) · Diabetes Care · doi:10.2337/dc10-1068 · Cited by 625
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284
Piccinni, C., Motola, D., Marchesini, G., & Poluzzi, E. (2011) · Diabetes Care · doi:10.2337/dc10-2412 · Cited by 239
Pioglitazone and Bladder Cancer
Tseng, C.-H. (2012) · Diabetes Care · doi:10.2337/dc11-1449 · Cited by 123 · cited 2×
“…with pioglitazone or rosiglitazone Odds Ratio Odds Ratio TZD safe TZD harmful Study or Subgroup Pioglitazone Azoulay 2012 [46] Chang 2012 [47] Hsiao 2013 [51] Lewis 2011 [41] Neumann 2012 [19] Song 2012 [52] Tseng 2012 [44] Wei 2013 [45] Weight IV, Fixed, 95% ClIV, Fixed, 95% Cl 0.5 0.7 1 1.5 2”
InfluentialLincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Cited by
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
Antoni, S., Ferlay, J., Soerjomataram, I., Znaor, A., Jemal, A., & Bray, F. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.010 · Cited by 2,514
Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018
Cumberbatch, M. G. K., Jubber, I., Black, P. C., Esperto, F., Figueroa, J. D., Kamat, A. M., Kiemeney, L., Lotan, Y., Pang, K., Silverman, D. T., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.09.001 · Cited by 820
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Epidemiology of urothelial carcinoma
Miyazaki, J., & Nishiyama, H. (2017) · International Journal of Urology · doi:10.1111/iju.13376 · Cited by 253
Pioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237
Metadata
- Authors
- Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2014-07-21
- Volume
- 78
- Issue
- 2
- Pages
- 258-273
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1752522506
- Cited by
- 127
- References
- 10
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis. https://app.cochat.ai/papers/10.1111/bcp.12306
- The paper
- Turner, R. M., Kwok, C. S., Chen‐Turner, C., Maduakor, C. A., Singh, S., & Loke, Y. K. (2014). Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta‐analysis. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.12306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.